Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
The University of Texas MD Anderson Cancer Center · Ochsner Health System · +2 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
336
total citations
- FWCI
- 33.07
- Percentile
- 100%
- References
- 48
Citations per year
Authors
37- YHYared Hailemichael
The University of Texas MD Anderson Cancer Center
- DHDaniel H. Johnson
Ochsner Health System, The University of Texas MD Anderson Cancer Center
- NANoha Abdel‐Wahab
The University of Texas MD Anderson Cancer Center, Assiut University Hospitals
- WCWai Chin Foo
The University of Texas MD Anderson Cancer Center
- SBSalah-Eddine Bentebibel
The University of Texas MD Anderson Cancer Center
Topics & keywords
Topics
Keywords
- Blockade
- Immunology
- Immune system
- Immunotherapy
- Colitis
- Immune checkpoint
- Medicine
- Autoimmunity
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- FFFoundation for the National Institutes of HealthAwards: R01HL141966, R01HL143520
- GGlaxoSmithKline
- MMerck
- SSanofi
- CPCancer Prevention and Research Institute of TexasAwards: UT MDACC CA016672, RP190326, K08AR079587, P30CA016672
- DMDr. Miriam and Sheldon G. Adelson Medical Research Foundation
- NINational Institutes of HealthAwards: P50CA221703, K01AI163412
- UOUniversity of Texas MD Anderson Cancer Center
- NCNational Cancer Institute